Global law firm Ashurst has advised MedinCell - listed on Euronext - a commercial-stage pharmaceutical technology company developing a portfolio of long-acting injectable products in a variety of therapeutic areas, on its €25 million capital raising.
Keep up to date
Sign up to receive the latest legal developments, insights and news from Ashurst. By signing up, you agree to receive commercial messages from us. You may unsubscribe at any time.
Sign up